Home  »  Trending   »  Why Moderna Inc. (MRNA)’s Most Recent Report Rev...

Why Moderna Inc. (MRNA)’s Most Recent Report Reveals Some Hints About Its Future

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Moderna Inc. (NASDAQ:MRNA) went up by 9.28% from its latest closing price compared to the recent 1-year high of $497.49. The company’s stock price has collected -0.57% of loss in the last five trading sessions. Barron’s reported 10 hours ago that Moderna CEO Resets Flu-Vaccine Expectations

Is It Worth Investing in Moderna Inc. (NASDAQ :MRNA) Right Now?

Moderna Inc. (NASDAQ:MRNA) scored a price-to-earnings ratio above its average ratio, recording 14.35 x from its present earnings ratio. Opinions of the stock are interesting as 7 analysts out of 19 who provided ratings for Moderna Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 7 rated it as “hold,” and 3 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free


The average price from analysts is $296.00, which is $55.23 above the current price. MRNA currently public float of 366.97M and currently shorts hold a 4.18% ratio of that float. Today, the average trading volume of MRNA was 11.75M shares.

MRNA’s Market Performance

MRNA stocks went down by -0.57% for the week, with a monthly drop of -14.15% and a quarterly performance of -23.40%, while its annual performance rate touched 99.30%. The volatility ratio for the week stands at 9.35% while the volatility levels for the past 30 days are set at 8.27% for Moderna Inc.. The simple moving average for the period of the last 20 days is -7.76% for MRNA stocks with a simple moving average of -15.32% for the last 200 days.

Analysts’ Opinion of MRNA

Wolfe Research, on the other hand, stated in their research note that they expect to see MRNA reach a price target of $304. The rating they have provided for MRNA stocks is “Outperform” according to the report published on November 09th, 2021.

Deutsche Bank gave a rating of “Sell” to MRNA, setting the target price at $250 in the report published on October 22nd of the previous year.

MRNA Trading at -14.16% from the 50-Day Moving Average

After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -53.02% of loss for the given period.

Volatility was left at 8.27%, however, over the last 30 days, the volatility rate increased by 9.35%, as shares sank -9.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -32.83% lower at present.

During the last 5 trading sessions, MRNA fell by -0.57%, which changed the moving average for the period of 200-days by +75.35% in comparison to the 20-day moving average, which settled at $252.19. In addition, Moderna Inc. saw -7.98% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MRNA starting from Bancel Stephane, who sale 10,000 shares at the price of $215.33 back on Jan 06. After this action, Bancel Stephane now owns 7,074,880 shares of Moderna Inc., valued at $2,153,300 using the latest closing price.

Bancel Stephane, the Chief Executive Officer of Moderna Inc., sale 9,000 shares at $232.10 during a trade that took place back on Jan 05, which means that Bancel Stephane is holding 5,779,535 shares at $2,088,900 based on the most recent closing price.

Stock Fundamentals for MRNA

Current profitability levels for the company are sitting at:

  • -94.99 for the present operating margin
  • +95.12 for the gross margin

The net margin for Moderna Inc. stands at -92.99. The total capital return value is set at -37.14, while invested capital returns managed to touch -36.66. Equity return is now at value 121.60, with 49.50 for asset returns.

Based on Moderna Inc. (MRNA), the company’s capital structure generated 9.28 points at debt to equity in total, while total debt to capital is 8.49. Total debt to assets is 3.24, with long-term debt to equity ratio resting at 8.09. Finally, the long-term debt to capital ratio is 7.41.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 6.96, with the company’s debt to enterprise value settled at 0.01. The receivables turnover for the company is 1.13 and the total asset turnover is 0.18. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.43.

Leave a Comment

Your email address will not be published. Required fields are marked *

Is Teradyne Inc. (TER) a Keeper?

Teradyne Inc. (NASDAQ:TER) went up by 3.99% from its latest closing price compared to the recent 1-year high of $168.91. The company’s stock price has




Download Free eBook For


100% free. stop anytime no spam